STTR Phase I: Bio-based Manufacturing of An Anticoagulant Precursor 4-Hydroxycoumarin

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1549724
Agency Tracking Number: 1549724
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: BT
Solicitation Number: N/A
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-01-01
Award End Date (Contract End Date): 2016-12-31
Small Business Information
220 Riverbend Rd, Athens, GA, 30602
DUNS: 079583193
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Yuheng Lin
 (706) 308-6165
Business Contact
 Yuheng Lin
Phone: (706) 308-6165
Research Institution
 University of Georgia Research Foundation Inc
 Yajun Yan
 310 East Campus Rd
Tucker Hall Room 409
ATHENS, GA, 30602
 Nonprofit college or university
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) project is to establish a bio-based manufacturing process for the production of the commodity chemical 4-hydroxycoumarin (4-HC) in an economical and renewable way. 4-HC is a direct synthetic precursor used to manufacture widely used oral anticoagulants, such as warfarin, acenocoumarol, and phenprocoumon. In addition, 4-HC-derived anticoagulants are commonly used as rodenticides to kill rodents. Traditionally, 4-HC is commercially manufactured through chemical synthesis using petro-related aromatic chemicals as starting materials, which is neither economical nor environmentally friendly. The proposed technology to be developed in this project is expected to dramatically lower the production cost, and reduce the reliance on petro chemicals. This STTR Phase I project proposes to create an optimal 4-HC-producing microbial strain that can be readily used for large-scale production. The strain is expected to have high genetic stability without the need for antibiotics or an inducer for production. Preliminary research has shown the microbial production of 4-HC from a renewable carbon source, glycerol, in shake flasks, which demonstrates great commercialization potential. However, the approach at this stage still uses host-plasmid systems that involve antibiotics and the inducer IPTG. This will not only increase the production cost but also will raise environmental concerns. Additionally, host-plasmid systems may cause instability in genetic properties, which is undesirable for large-scale production of commodity chemicals. To address these issues and achieve the goal of this STTR Phase I project, the following research objectives will be pursued: Integration of constitutively expressed 4-HC biosynthetic pathway genes into E. coli chromosomal DNA and its optimization; and inactivation of the E. coli endogenous enzymes responsible for unwanted degradation of 4-HC biosynthetic intermediates.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government